EMEri Mori

Eri Mori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eri Mori has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in the Epidemiology of Pediatric Olfactory Dysfunction Before and After COVID ‐19 Pandemic

    by Yuji Kishimoto, Eri Mori, Rinko Sakurai, Hirotaka Tanaka, Monami Nagai, Rumi Sekine, Masayoshi Tei, Nobuyoshi Otori

    Background: The COVID‐19 pandemic may have altered the epidemiology and clinical features of pediatric olfactory dysfunction, but data focusing on children remain limited, particularly regarding etiological changes and qualitative symptoms such as parosmia. This study investigated temporal changes in pediatric presentations at a tertiary smell clinic. Methodology/Principal: We retrospectively reviewed patients younger than 18 years who visited our clinic for olfactory dysfunction between January 2009 and December 2024. Patients were divided into pre‐pandemic (January 2009–March 2020) and post‐pandemic (April 2020–December 2024) cohorts. Etiology was determined using clinical history, imaging, nasal endoscopy, and psychophysical and subjective olfactory tests. Results: The proportion of pediatric patients among all patients with olfactory dysfunction increased significantly from 1.5% (35/2322) in the pre‐pandemic cohort to 4.7% (48/1022) in the post‐pandemic cohort ( p < 0.01), with a corresponding decrease in adults. Etiological distribution shifted significantly ( p < 0.01): olfactory cleft stenosis predominated in pre‐pandemic, whereas upper respiratory tract infection became the leading cause in the post‐pandemic cohort, 76% of cases of which related to COVID‐19. Parosmia was observed exclusively in post‐COVID‐19 pediatric patients. Subjective olfactory scores were higher with post‐pandemic patients, indicating more mildly perceived dysfunction, while psychophysical test results showed no significant differences. Conclusions: After the COVID‐19 pandemic, pediatric olfactory dysfunction became more frequent and was predominantly associated with post‐infectious causes, particularly COVID‐19, with parosmia emerging as a characteristic feature. Greater clinical awareness and pediatric‐specific diagnostic standards will be needed. Level of Evidence: Level 3.

  • Open Access

    Elezanumab Accelerates Post‐Injury Regeneration of Olfactory Sensory Neurons in a Methimazole‐Induced Mouse Model

    by Eri Mori, Rumi Ueha, Hirotaka Tanaka, Hironobu Nishijima, Masayoshi Kobayashi, Nobuyoshi Otori, Kenji Kondo

    Key Points: Elezanumab accelerates olfactory sensory neuron regeneration in a methimazole‐induced mouse model. Repulsive guidance molecule A blockade increases GAP43+ and OMP+ cells dorsally while sparing basal cells. This approach offers a novel therapy for sensorineural olfactory disorder.

  • Open Access

    Optimizing Odorants for Olfactory Training Based on Olfactory Receptor–Ligand Pair Analysis

    by Hironobu Nishijima, Eric H. Holbrook, James E. Schwob, Eri Mori, Ryoji Kagoya, Kei Ogawa, Kyohei Horikiri, Kenji Kondo

    Objective: To optimize olfactory training (OT) by identifying a scientifically grounded combination of odorants that maximally stimulate human olfactory receptors (ORs) through the utilization of a comprehensive receptor–ligand interaction dataset. Methods: We analyzed 75,050 OR–odor pair experiments from the M2OR database, focusing on 385 unique human ORs and 510 unique odorants. Utilizing human olfactory epithelium transcriptomic data, we identified highly abundant ORs and evaluated their interactions with various odorants to determine the optimal odorant combination for maximizing OR stimulation. The effectiveness of the classical OT odorants (rose, lemon, eucalyptus, and clove) in maximal OR stimulation was also evaluated and compared to the optimal odor combination. Results: A novel four‐odorant combination (galaxolide, eugenol acetate, [−]‐menthol, and geranyl acetate) would stimulate 323 ORs (83.9% of 385 ORs), covering 69.9% of estimated OR expression. In comparison, the classical four OT odor mixture would stimulate 151 ORs (39.2% of 385 ORs), covering 32.9% of estimated OR expression. Both odorant combinations stimulated a large proportion of highly abundant ORs, presumed to be functionally important. These findings suggest that while the classical odors have a substantial effect, the novel odorant combination has the potential to offer significantly broader receptor activation and improved outcomes in OT. Conclusion: This receptor‐based approach provides a scientifically grounded method for optimizing OT. Further clinical validation is necessary to confirm the therapeutic efficacy of this approach. Level of Evidence: 4.


  • Open Access

    Olfactory cleft obstruction in post-COVID-19 olfactory disorder: CT Comparison with post-viral cases

    by Hirotaka Tanaka, Eri Mori, Yuji Kishimoto, Nagomi Yonezawa, Rumi Sekine, Monami Nagai, Masayoshi Tei, Nobuyoshi Otori

    SUMMARY: Background: Post-COVID-19 olfactory dysfunction (PCOD) is a common sequela of SARS-CoV-2 infection, with some cases persisting beyond the acute phase. While prolonged PCOD has been considered primarily sensorineural, recent studies suggest that olfactory cleft (OC) obstruction may contribute to olfactory dysfunction (OD). This study aimed to investigate OC obstruction in prolonged PCOD compared to post-infectious olfactory dysfunction (PIOD) and assess its impact on olfactory function. Methodology/Principal: We retrospectively analysed sinus computed tomography scans of patients with prolonged PCOD and PIOD. OC obstruction was classified into absent (0%), mild (1–90%), and severe (>90%) types. The severity of OC obstruction was compared between PCOD and PIOD cases, and olfactory test results were analysed according to OC obstruction severity. Results: A total of 87 PCOD patients and 67 PIOD patients were included. Mild and severe OC obstruction was more prevalent and severe in prolonged PCOD (mild: 35.6%, severe: 18.4%) than PIOD (mild: 13.4%, severe: 3%). Moreover, worsened olfactory function was found in PCOD patients with severe OC obstruction. In contrast, OC obstruction showed little association with olfactory function in PIOD patients. Conclusions: Mild and Severe OC obstruction appear to be more common in prolonged PCOD. Moreover, severe OC obstruction may further impair olfactory function in PCOD patients. Conversely, severe OD in PIOD patients occurred independently of OC obstruction .

  • Open Access

    The Development and Validation of the Smell‐Qx Questionnaire, Based on a Systematic Review of the Literature and the COMET Initiative on the Development of Core Outcome Sets for Clinical Trials in Olfactory Disorders

    by Matt Lechner, Alexander Fjaeldstad, Umar Rehman, Jacklyn Liu, David Boniface, Jim Boardman, Duncan Boak, Aytug Altundag, Johannes Frasnelli, Simon Gane, et al.

    Background: Olfactory dysfunction affects up to 22% of the population. Accurate assessment is vital for diagnosis and tracking outcomes, often using patient‐reported outcome measures (PROMs).Aims: We aimed to develop and validate a novel questionnaire for assessing olfactory and gustatory dysfunction.Methods: A systematic review identified existing smell and taste questionnaires, followed by item generation and selection. After two Delphi cycles and consultation with a large panel of smell and taste experts, the Smell‐Qx questionnaire was developed. A validation study recruited patients from smell and taste clinics (cases) and general ENT clinics (controls) to complete the Smell‐Qx. Additionally, patients with smell and taste disorders underwent psychophysical testing using Sniffin’ Stick Threshold, Discrimination, and Identification (TDI) tests.Results: The Smell‐Qx is an 11‐domain instrument, with five core domains used for total score calculation and six history/quality‐of‐life domains for obtaining a comprehensive history. The validation study recruited 60 participants (32 patients with smell/taste disorders and 28 controls). Items showed acceptable to significant internal consistency (Cronbach's α: 0.64–0.97) and test–retest reliability (ICC: 0.65–0.99, p < 0.001). The Smell‐Qx was effective at distinguishing patients with smell and taste disorders from controls (t = 9.99, df = 58, p < 0.0001). Concurrent criterion validity was good with overall SATD‐related quality of life (r = 0.43, p = 0.015), as well as with the smell loss domain and overall smell TDI scores (r = −0.54, p = 0.011).Conclusion: The Smell‐Qx is a reliable and valid PROM for assessing olfactory and self‐reported gustatory disorders, capturing symptom severity and quality‐of‐life impact. It can integrate into a multi‐modal assessment approach alongside psychophysical testing.


  • Assessing parosmia patients: a study on the evaluation method using a self-administered odor questionnaire for parosmia

    by M. Tei, E Mori, N Yonezawa, Y Kishimoto, H Tanaka, N Yanagi, Y Tsurumoto, M Nagai, R Sekine, N Otori, et al.

    Background: Parosmia symptoms are difficult to quantify due to their heterogeneity among patients, and thus a clinical challenge. This study aimed to assess parosmia with Self-Administered Odor Questionnaire for Parosmia (SAOQ-P), a modification of the widely used SAOQ in Japan. The primary objective was to assess the effectiveness of SAOQ-P in identifying parosmia symptoms and its potential integration into the clinical assessment process. The study also explored traditional olfactory test differences between patients with and without parosmia. Methods: Patients at Jikei Smell Clinic that presented between May 2022 and November 2022 were recruited and administered the SAOQ-P, which had an added question about changes in the perception of 20 daily odors compared to the original SAOQ. Traditional olfactory tests utilized T&T olfactometry and Open Essence. Results: Of 279 patients, 81 had parosmia, while 198 did not exhibit parosmic symptoms. Parosmia prevalence was influenced by the cause of olfactory dysfunction, with post-infectious and post-COVID-19 patients showing higher parosmia rates. Among parosmia patients, 87% reported changes in their perception of at least one odor assessed by SAOQ-P, with coffee, stool, and perfume most commonly affected. Traditional olfactory tests showed no significant differences between parosmia and non-parosmia groups. The number of odors causing parosmia was negatively correlated with age. Conclusion: SAOQ-P offers a promising approach to assess and quantify parosmia symptoms, seamlessly integrating into clinical assessments. SAOQ-P identified parosmia in 87% of patients and revealed insights into triggering factors. Traditional olfactory tests' limitations underscore the need for more accurate, patient-centric diagnostic approaches for parosmia.


  • A Nationwide survey of safety protocols and chemosensory assessments by Japanese clinicians pre- and post-COVID-19 pandemic

    by Ayaho Yoshino, Ryosuke Murakami, Kei Hosoya, Taro Komachi, Eri Mori, Tomomi Nin, Mehmet K. Mahmut, Kimihiro Okubo